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Background: Autism spectrum disorder (ASD) is now understood to have multiple genetic risk genes and one
example is SHANK3. SHANK3 deletions and mutations disrupt synaptic function and result in Phelan-McDermid
syndrome (PMS), which causes a monogenic form of ASD with a frequency of at least 0.5% of ASD cases. Recent
evidence from preclinical studies with mouse and human neuronal models of SHANK3 deficiency suggest that
insulin-like growth factor-1 (IGF-1) can reverse synaptic plasticity and motor learning deficits. The objective of this
study was to pilot IGF-1 treatment in children with PMS to evaluate safety, tolerability, and efficacy for core deficits
of ASD, including social impairment and restricted and repetitive behaviors.
Methods: Nine children with PMS aged 5 to 15 were enrolled in a placebo-controlled, double-blind, crossover
design study, with 3 months of treatment with IGF-1 and 3 months of placebo in random order, separated by a
4-week wash-out period.
Results: Compared to the placebo phase, the IGF-1 phase was associated with significant improvement in both
social impairment and restrictive behaviors, as measured by the Aberrant Behavior Checklist and the Repetitive
Behavior Scale, respectively. IGF-1 was found to be well tolerated and there were no serious adverse events in any
participants.
Conclusions: This study establishes the feasibility of IGF-1 treatment in PMS and contributes pilot data from the first
controlled treatment trial in the syndrome. Results also provide proof of concept to advance knowledge about
developing targeted treatments for additional causes of ASD associated with impaired synaptic development and
function.Background
Autism spectrum disorder (ASD) is currently a diagnosis
established by behavioral criteria but its etiology resides
in complex genetics, and many distinct genetic risk genes
have been identified as causal. One such example is the
SHANK3 gene located on the terminal end of chromo-
some 22q where loss of one copy (haploinsufficiency)
of SHANK3 causes a monogenic form of ASD with a* Correspondence: alexander.kolevzon@mssm.edu
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unless otherwise stated.frequency of at least 0.5% of ASD cases [1-4]. The
SHANK3 gene codes for a protein that plays a critical
role in synaptic function by scaffolding the postsynaptic
density of glutamatergic synapses [5] and its loss is suffi-
cient to cause Phelan-McDermid syndrome (PMS) [6,7].
PMS is characterized by significant intellectual disability
(ID), severely delayed or absent language, and ASD. Af-
fected individuals also suffer from a heterogeneous array
of dysmorphic and medical features, including increased
risk of seizures, recurring infections, hypotonia, renal
disease, and gastroesophageal reflux [8-17]. While PMS
accounts for a relatively small proportion of ASD cases,
the SHANK3 pathway is relevant to many forms of ASDal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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eral common pathways, including SHANK3 [18,19].
Using Shank3-deficient mice, deficits in synaptic function
and plasticity have been shown using electrophysiological
measures [20]. Behaviorally, Shank3-deficient mice display
motor deficits, less social sniffing and reduced ultrasonic
vocalizations as compared to wildtype controls [20,21].
Insulin-like growth factor-1 (IGF-1) has been studied in this
mouse, as well as in human neuronal models of PMS, and
was found to reverse synaptic and behavioral deficits [21].
Importantly, IGF-1 is also effective in reversing phenotypic
changes in human neuronal models of Rett syndrome [22],
providing additional evidence that this pathway may be a
target in diverse forms of ASD. These data are promising
and provide preclinical evidence that IGF-1 may produce
disease-modifying effects in subjects with PMS or Rett syn-
drome. Recent evidence also provides preliminary support
of efficacy with IGF-1 in children with Rett syndrome [23].
IGF-1 is a commercially available compound that crosses
the blood-brain barrier (BBB) and has beneficial effects on
synaptic development by promoting neuronal cell survival,
synaptic maturation, and synaptic plasticity [23,24]. IGF-1
enters the brain from the circulation where it is re-
leased mainly by the liver upon growth hormone stimula-
tion. Blood-borne IGF-1 is found in the central nervous
system (CNS) where it promotes brain vessel growth [25],
neurogenesis, and synaptogenesis [26]. The mechanisms
that trigger IGF-1 entry through the BBB are proposed to
occur by diffusible messengers released in areas of neur-
onal activity which lead to cleavage of IGF binding
protein-3 (IGFBP-3) to increase free IGF-1 and allow pas-
sage of circulating IGF-1 into the CNS [27]. The recent
IGF-1 study in Rett syndrome examined its pharmacoki-
netic profile in human subjects and found that IGF-1
reached the CNS compartment as demonstrated by signifi-
cantly increased cerebrospinal fluid levels after treatment
[23]. However, the precise mechanisms by which IGF-1 ex-
erts its effects on the CNS remains an active area of study.
IGF-1 is currently approved by the Food and Drug
Administration (FDA) for the treatment of short stature
due to primary IGF-1 deficiency (Laron’s Dwarfism).
There have been no controlled treatment trials in PMS to
date and this study was designed to evaluate the safety,
tolerability, and efficacy of IGF-1 versus placebo in chil-
dren with PMS targeting core domains of ASD. Specific-
ally, social deficits and repetitive behaviors were measured
using the Aberrant Behavior Checklist-Social Withdrawal
(ABC-SW) subscale as the primary outcome measure [28]
and the Repetitive Behavior Scale-Revised (RBS-R) as a
secondary outcome [29].
Methods
All subjects were recruited under an Institutional Review
Board (IRB) approved protocol as part of ongoing studiesin PMS at the Seaver Autism Center for Research and
Treatment at the Icahn School of Medicine at Mount
Sinai and parents/guardians provided informed con-
sent. Treatment followed a randomized, placebo-controlled,
crossover format with 12 weeks in each treatment arm
(IGF-1 and placebo), separated by a 4-week wash-out
phase (ClinicalTrials.gov Identifier: NCT01525901). This
was a pilot study in a rare disorder, PMS, and sample size
and analyses were defined a priori. Multiple outcome
measures are being collected as part of a larger ongoing
clinical trial with IGF-1 in PMS but pilot data from the
safety measures, and main primary and second outcomes
have been analyzed to date and are presented herein.
Inclusion criteria
This pilot recruited 9 children between 5 and 15 years-
old with PMS and confirmed to have SHANK3 deletions
or mutations based on chromosomal microarray or high-
throughput or targeted sequencing. All subjects were on
stable medication regimens for at least 3 months prior to
enrollment.
Exclusion criteria
Cases were excluded if any of the following were applic-
able: 1) closed epiphyses; 2) active or suspected neopla-
sia; 3) intracranial hypertension; 4) hepatic insufficiency;
5) renal insufficiency; 6) cardiomegaly/valvulopathy; 7)
allergy to IGF-1; 8) patients with comorbid conditions
deemed too medically compromised to participate.
Drug administration
IGF-1 (Increlex; Ipsen Biopharmaceuticals, Inc) is an
aqueous solution for injection containing human insulin-
like growth factor-1 (rhIGF-1) produced by recombinant
DNA technology. Placebo consisted of saline prepared in
identical bottles by the research pharmacy at Mount Sinai.
We received an Investigational New Drug exemption from
the Food and Drug Administration (#113031) to conduct
this trial in children with PMS. Based on the package in-
sert for Increlex, dose titration was initiated at 0.04 mg/kg
twice daily by subcutaneous injection, and increased, as
tolerated, every week by 0.04 mg/kg per dose to a max-
imum of 0.12 mg/kg twice daily. This titration was jus-
tified based on our preclinical data, which indicated
that 0.24 mg/kg/day is effective in reversing electro-
physiological deficits whereas 0.12 mg/kg/day was not as
effective [21]. We aimed to reach the therapeutic dose
as quickly as is safe and tolerated in order to allow
maximum time for clinical improvement. Doses could
be decreased according to tolerability by 0.04 mg/kg per
dose. Medication was administered twice daily with
meals, and preprandial glucose monitoring was per-
formed by parents prior to each injection throughout
the treatment period. Parents were carefully trained










1 177.4 8.5 29
2 103.7 10.3 47
3 66.3 11.3 52
4 64.6 12.3 43
5 109.7 a36 61
6 91.8 7 50
7 172.7 30.5 31
8 71.1 a31 51
9 61.8 9.3 45
aDenotes scores from the Leiter International Performance Scale-Revised; all
other scores were based on the Mullen Scales for Early Learning.
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and medication administration.
Outcome measures
Efficacy measurements were taken at baseline of each
treatment phase, and at weeks 4, 8, and 12 of each treat-
ment phase. The ABC is a rating scale used to monitor
an array of behavioral features, including social withdrawal
(i.e., Lethargy subscale). The ABC-SW subscale was chosen
a priori as the primary outcome measure because it is
well validated in both ID and ASD patients and is cur-
rently accepted as an appropriate outcome measure within
the field of pediatric psychopharmacology research. In
addition, preliminary data suggest that the ABC accurately
reflects ASD-related deficits in PMS. Repetitive behavior
was measured using the RBS-R, which has also been pre-
viously validated as a measurement tool in ID and ASD
populations. Safety, tolerability, and adverse events (AEs)
were measured throughout the trial during monitoring
visits and phone calls using an adapted semi-structured
interview, the Safety and Monitoring Uniform Report
Form (SMURF) every 2 weeks, and extensive clinical and
laboratory assessments every 4 weeks. AEs were docu-
mented with respect to severity, duration, management,
relationship to study drug, and outcome.
Data analysis
This trial used a randomized crossover design; thus, order
(phase) of assessment is nested (repeated) within treat-
ment and treatment is nested within subjects. Given the
small sample size, we considered several analytic strategies
and selected a fully within-subject, repeated-measures de-
sign. To conform to intent-to-treat principles, we used
mixed effects regression models so that participants miss-
ing observations would be included in the analysis (full
information maximum likelihood estimation). Treatment
was dummy coded as 0 = placebo and 1 = control and time
coded naturally as weeks (0, 4, 8, and 12). In this analysis,
the primary focus was time by treatment interaction,
which estimates the differential change in the two treat-
ments on the outcome measures. Because of the small
sample size, we used a variance components intercept only
model for the random effect variation. We then added
‘phase’ as another repeated factor to examine the effect of
order through a three-way interaction analysis.
Results
A total of 9 children and adolescents (6 females and 3
males) were screened based on the established diagnosis
of PMS and all 9 were randomized to treatment order.
Subjects ranged in ages from 5 to 15 years old at the
time of entry into the study (X = 8.6 years; SD = 4.0). At
baseline, the mean ABC-SW subscale score was 16.9
(SD = 8.7) for all subjects and the mean RBS-R Totalscore was 32.1 (SD = 23.5). Cognitive abilities were eval-
uated with the Mullen Scales for Early Learning [30] or
the Leiter International Performance Scale-Revised [31]
and adaptive functioning with the Vineland Adaptive
Behavior Scales, Second Edition [32]. All participants met
criteria for ID based on mental age equivalent scores on
IQ measures and adaptive behavior composite scores (see
Table 1). The Leiter was the preferred measure of non-
verbal IQ in our sample given the potential to calculate
standard scores in this age range. However, only two of
nine participants had the pre-requisite skills to participate
in a Leiter administration based on the ability to make a
two-part discrimination, sit, and attend. For the remaining
7 of 9 participants, we used the Mullen despite the fact
that the upper end of the Mullen standardization sam-
ple is 68 months. All subjects met criteria for ASD
according to expert clinical consensus and results from
the Autism Diagnostic Observation Schedule-Generic [33],
the Autism Diagnostic Interview-Revised (ADI-R; [34]),
and the Diagnostic and Statistical Manual for Mental
Disorders-5 [35].
Because this was a small pilot trial, our primary focus
was on safety. IGF-1 was generally well tolerated and
there were no serious adverse events (SAEs) (see Table 2).
The most common side effects during the IGF-1 treat-
ment phase were sleep disturbance (N = 7); hypoglycemia
((<50 mg/dL) (7 occurrences; N = 5)), constipation (N = 4),
increased appetite (N = 4), and mood changes or increased
irritability (N = 4). Other less common AEs ‘possibly’ or
‘probably related’ to IGF-1 and worth noting included
decreased appetite (N = 2), increased urinary frequency
(N = 1), hair loss (N = 1), rash (N = 1), and soft tissue swell-
ing of the nose (N = 1). The rash resolved upon discontinu-
ing IGF-1 and did not recur upon re-challenge. The soft
tissue swelling also resolved upon completion of the treat-
ment phase without intervention or dose adjustment. One
Table 2 Adverse events
Adverse events IGF-1 Placebo
Constipation 4 3
Sedation 1 0
Decreased appetite 2 3
Periobital/facial swelling 1 0
Diarrhea 1 2
URTIa 5 5
Sleep Disturbance 7 2
Increased appetite 4 0
Mood changes/irritability 4 2
Increased thirst 1 0
Increased phlegm 1 0
Teeth grinding 1 0
Cough 1 2
Hand flapping 1 0
Increased bowel movements 1 0
Increased chewing/biting 1 0
Decreased visual acuity 1 0
Lethargy/decreased energy 1 1
Cooler body temperature/sweating 1 0
Runny nose/congestion 1 1
Gait changes/fell 1 2
Stomach virus 1 1
Anxiety 0 2
Increased urine frequency 2 0
Fever 3 3
Increased energy 1 0
Gagging 1 0
Increased thirst 0 1
Conjunctivitis 1 0
Erythema/swollen eyes 1 0
Vomiting 1 1
Rash 3 0
Nose swelling 1 0
Warmer body temperature 1 0
Hair loss 1 0
Increased aggression 1 0
Hypoglycemiab 7 3
aURTI = upper respiratory tract infection. bHypoglycemia was defined by
glucose < 50 mg/dL and occurred in 5/9 patients while on IGF-1 and in
2/9 patients while on placebo.
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upper respiratory tract infection requiring antibiotics that
led to gastrointestinal symptoms, constipation, and de-
creased appetite and they could not adequately sustain
their glycemic state to tolerate treatment. At the earlytermination visit, the patient was fully recovered without
sequelae. No other patients required dose adjustments
during the trial. Many of the same AEs were likely to
occur among patients during the placebo phase, including
hypoglycemia (3 occurrences; N = 2), albeit less frequently;
significantly more AEs were reported when patients were
taking IGF-1 than placebo (P = 0.0015). There were no
significant changes in growth parameters, including
height, weight, head circumference, or bone age over the
course of the trial.
In terms of efficacy, when participants received IGF-1
they showed significant improvement as compared to
when they were on placebo (see Figures 1 and 2). There
was a significant two-way time x group interaction across
both phases on the ABC-SW subscale (N = 9; t = −2.107;
P = 0.040). Importantly, when ‘phase’ (order) was added as
a third variable, the three-way interaction of group x time
x phase was not significant. This indicates that the time x
group interaction is not significantly different as a func-
tion of treatment order and the two-way interaction is a
valid reflection of the drug effect. Inspection of a longitu-
dinal plot of the data suggested that the drug condition
showed improvement in both phases whereas the placebo
group showed little change in either phase.
However, participants assigned to IGF-1 at phase 1
had a higher baseline ABC-SW value at phase 1 than the
placebo participants. Given the small sample size, this
disparity is not surprising despite randomization. To ac-
count for this disparity we controlled for phase 1 ABC-
SW baseline values and the time x treatment interaction
remained significant (N = 9; t = −2.151; P = 0.036). Analyses
were performed on the other ABC subscales and results
were not statistically significant (Irritability: t = −0.839,
P = 0.405; Motor Stereotypies: t = −0.240, P = 0.811;
Hyperactivity: t = −0.954, P = 0.344; Inappropriate Speech:
t = 0.008, P = 0.994).
Results from the RBS-R Total score were not significant
(N = 9, t = −0.791; P = 0.432). However, analyses were per-
formed on the RBS-R subscales and significant improve-
ment was found on the Restricted Behavior subscale
(N = 9; t = −2.077; P = 0.042). Again, when ‘phase’ (order)
was added as a third variable, the three-way interaction
was not significant indicating that the significant time x
group interaction is not a function of treatment order.
Participants also had a higher baseline RBS-R Restrictive
Behavior scores at phase 1 than the placebo partici-
pants, but after adding the baseline values of the RBS-R
Restricted Behavior subscale to the model, the interaction
remains significant and is largely unchanged (t = −2.107;
P = 0.040). Results from the other RBS-R subscales were
not statistically significant (Stereotyped Behavior: t = −0.269,
P= 0.789; Self-Injurious Behavior: t =−1.896, P= 0.063;
Compulsive Behavior: t = 0.888, P= 0.378; Ritualistic Behav-
ior: t =−0.192, P= 0.848; Sameness: t = 0.005, P= 0.996).
Figure 1 ABC-SW score between baseline and week 12 of drug or placebo. (A) Change in ABC-SW score between baseline and week 12 of
drug or placebo for 9 subjects. In this and all subsequent figures, treatment condition (drug versus placebo) was combined across treatment
phases. Error bars = ±1 SE. (B) Mean change in ABC-SW score between baseline and week 12 of drug or placebo. P = 0.040; error bars = ±1 SE.
ABC-SW= Aberrant Behavior Checklist Social Withdrawal subscale; SE = standard error. The star reflects the p value and notes the significance.
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Figure 2 RBS-R Restricted Behavior score between baseline and week 12 of drug or placebo. (A) Change in RBS-R Restricted Behavior
score between baseline and week 12 of drug or placebo. (B) Mean change in RBS-R Restricted Behavior score between baseline and week 12
of drug or placebo. P = 0.042; error bars = ±1 SE. RBS-R = Repetitive Behavior Scale-Revised. SE = standard error. The star reflects the p value
and notes the significance.
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This is the first controlled treatment trial in PMS and
establishes safety and preliminary evidence of benefit of
IGF-1 on core symptoms of ASD. Although PMS is now
recognized to be a relatively common cause of ASD, a
review of the literature revealed only two published re-
ports of medication treatment trials, one case series with
intranasal insulin [36] and one case study with risperi-
done [37], both open label and with reported improve-
ment. In the intranasal insulin study, 6 children received
up to 12 months of treatment with improvement based on
sum of scores from a parental questionnaire in most
domains, including cognitive, speech and language, and
motor skills [36]. Insulin was hypothesized in these cases
to improve neuronal function by increasing CNS glucose
uptake and enhancing synaptic plasticity via glutamatergic
receptors. Results from the case study with risperidone
were similarly optimistic but equally uncontrolled: an 18-
year-old girl with PMS was treated with risperidone
0.5 mg twice daily with significant improvement on the
Clinical Global Impression Scale (CGI; [38]) in anxiety, ag-
gression, and insomnia after 1 month that was sustained
after 6 months. The hypothesized mechanism of action of
risperidone in SHANK3 deficiency was to promote N-
methyl-D-aspartate (NMDA) transmission via dopamine 2
receptor blockade. However, studies in Shank3 deficient
mice indicate that reduced basal neurotransmission at
glutamatergic synapses may be α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor medi-
ated [20].
To date, few pharmacological treatments in ASD have
been developed based on neurobiological strategies. Most
trials have employed etiologically heterogeneous samples
and targeted associated symptoms. More recently, genetic
discovery and model systems have led to important op-
portunities for developing novel, potentially disease-
modifying therapeutics. This study is based on preclinical
evidence showing that IGF-1 reversed deficits in mouse
and neuronal models of SHANK3 deficiency. The results
now provide preliminary evidence of efficacy with IGF-1 in
a clinical sample of children with PMS. Recent examples of
a similar approach to treatment development are the
large-scale clinical trials currently underway in fragile X
syndrome (FXS), Rett syndrome, and tuberous sclerosis,
all known causes of ASD. The SHANK3/glutamate signal-
ing pathway is highly relevant to various forms of ASD
[18,19] and the link between deficits in synapse function
and ASD suggest that treatment with IGF-1 may have
implications for ASD caused by disruptions in common
underlying pathways. Importantly, the first evidence of the
efficacy of IGF-1 in an ASD-related syndrome has already
emerged in Rett syndrome [23].
Despite the promise of these findings, several weaknesses
must be acknowledged. For example, the small samplechallenges our ability to generalize results to a broader
population of children with PMS. The resulting decrease
in statistical power did not compromise the significance of
our findings but it is possible that the effect size may
not be upheld in a larger sample. In addition, we showed
that when patients received IGF-1 they were significantly
more likely to report AEs and this may have introduced
bias and contributed to the caregivers’ anticipation of
benefit. Such challenges are inherent to using caregiver re-
ports as outcome measures. Further, while patients were
more likely to report AEs while on IGF-1, the nature of
AEs was similar between treatment groups. Lastly, cross-
over trial designs carry risks of treatment order effects.
We provided a 4-week wash-out period to minimize this
risk and evaluated the differential effect of treatment over
time in the context of order to show that there was no
significant effect of treatment order. We chose to use this
design because PMS is a rare disease without available
treatments and wanted to ensure that all participants were
afforded the opportunity to receive active medication; the
cost of IGF-1 prohibited an open label extension trial.
Conclusions
Results from this study are novel and of broad interest for
a number of important reasons. First, PMS, while consid-
ered a rare disorder, is now known to be a more common,
and highly penetrant cause of ASD [39]. As such, there is
significant interest in the SHANK3 gene as genetic discov-
ery and functional analysis of model systems continue to
aid in our understanding of the neurobiology of ASD. Sec-
ond, this is a translational clinical trial based on prior
work in mice that demonstrates IGF-1 to reverse electro-
physiological and motor learning deficits [21]. Third, an
independent group has demonstrated a reversal of synap-
tic deficits with IGF-1 in neurons derived from induced
pluripotent stem cells of patients with PMS [21]. Fourth,
there is now additional independent clinical evidence of
the efficacy of IGF-1 in Rett syndrome to generate interest
in this compound. Finally, we have shown benefits with
IGF-1 on core symptoms of ASD, suggesting a potentially
disease-modifying effect. Of course, these positive findings
must be interpreted with caution given the small sample
size. With its limitations, the present study nevertheless
contributes the first evidence of the safety and efficacy of
IGF-1 in PMS from the first controlled treatment trial in
the field. Results from this pilot are intended to facilitate
larger studies that will more definitively inform efficacy.
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